Gilenya offers even more benefits than previously realized
While this is interesting news, but imo. its "only" relevant from a scientific point of view as opposed to direct patients interest. After all, the published results from clinical trials (MRI lesion, annual relapse rate, EDSS progression etc.) are what they are. The mechanism of action - other than the modification of the immune response - underlying these outcomes is interesting (e.g. for the development of new drugs) but imo. not relevant for a patients therapy-decision whatsoever.
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.